Recro Pharma, Inc. 4
4 · Recro Pharma, Inc. · Filed Mar 16, 2017
Insider Transaction Report
Form 4
SCP Vitalife Partners II LP
10% Owner
Transactions
- Sale
Common Stock
2017-03-15$8.01/sh−19,161$153,522→ 2,257,410 total - Sale
Common Stock
2017-03-16$7.93/sh−9,488$75,200→ 2,247,922 total - Sale
Common Stock
2017-03-14$8.04/sh−16,328$131,271→ 2,276,571 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.73 to $8.26, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.84 to $8.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.